Understanding the Effects of Risankizumab on Health Over Time

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

10 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study aims to evaluate how Risankizumab, a medication used to treat Crohn's Disease, works in children. It focuses on understanding how factors such as age, weight, and the way the drug is processed in the body may influence its effectiveness and safety in pediatric patients.

Eligibility & Criteria

IRB #:
24-021971
Official Title:
Risankizumab in Children with Crohn's Disease: A Multi-Center PORTO Group Prospective Study
Study Phase:
Not Applicable
Eligible Age Range:
1 Months - 17 Years
Gender:
All
Study Categories:

Visit Criteria

Participation will last for approximately 3 years and involve 8 study visits. Each visit will include a study questionnaire and a physical examination, if one was not completed at a recent office visit. The study team will also look through participants' medical records for demographic, medication, and disease activity data.

Leader
Ronen Stein

Ronen Stein, MD